 Fluoroquinolones
"Fluoroquinolones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of QUINOLONES with at least one fluorine atom and a piperazinyl group.
| Descriptor ID |
D024841
|
| MeSH Number(s) |
D03.438.810.835.322
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Fluoroquinolones".
Below are MeSH descriptors whose meaning is more specific than "Fluoroquinolones".
This graph shows the total number of publications written about "Fluoroquinolones" by people in UAMS Profiles by year, and whether "Fluoroquinolones" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 0 | 1 | 1 | | 2019 | 2 | 0 | 2 | | 2017 | 1 | 0 | 1 | | 2016 | 1 | 1 | 2 | | 2015 | 2 | 0 | 2 | | 2014 | 0 | 1 | 1 | | 2013 | 0 | 1 | 1 | | 2011 | 1 | 2 | 3 | | 2010 | 0 | 1 | 1 | | 2007 | 1 | 0 | 1 | | 2006 | 2 | 0 | 2 | | 2005 | 1 | 2 | 3 | | 2001 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 1992 | 1 | 0 | 1 | | 1991 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Fluoroquinolones" by people in Profiles over the past ten years.
-
Syed RR, Catanzaro DG, Colman RE, Cooney CG, Linger Y, Kukhtin AV, Holmberg RC, Norville R, Crudu V, Ciobanu N, Codreanu A, Seifert M, Hillery N, Chiles P, Catanzaro A, Rodwell TC. Clinical Evaluation of the XDR-LFC Assay for the Molecular Detection of Isoniazid, Rifampin, Fluoroquinolone, Kanamycin, Capreomycin, and Amikacin Drug Resistance in a Prospective Cohort. J Clin Microbiol. 2023 03 23; 61(3):e0147822.
-
Seifert M, Capparelli E, Catanzaro DG, Rodwell TC. Using Mycobacterium tuberculosis Single-Nucleotide Polymorphisms To Predict Fluoroquinolone Treatment Response. Antimicrob Agents Chemother. 2019 07; 63(7).
-
Mavros MN, Theochari NA, Kyriakidou M, Economopoulos KP, Sava JA, Falagas ME. Fluoroquinolone-based versus ?-lactam-based regimens for complicated intra-abdominal infections: a meta-analysis of randomised controlled trials. Int J Antimicrob Agents. 2019 Jun; 53(6):746-754.
-
Seifert M, Georghiou SB, Garfein RS, Catanzaro D, Rodwell TC. Impact of Fluoroquinolone Use on Mortality Among a Cohort of Patients With Suspected Drug-Resistant Tuberculosis. Clin Infect Dis. 2017 Sep 01; 65(5):772-778.
-
Mitsugi R, Itoh T, Fujiwara R. MicroRNA-877-5p is involved in the trovafloxacin-induced liver injury. Toxicol Lett. 2016 Nov 30; 263:34-43.
-
Georghiou SB, Seifert M, Lin SY, Catanzaro D, Garfein RS, Jackson RL, Crudu V, Rodrigues C, Victor TC, Catanzaro A, Rodwell TC. Shedding light on the performance of a pyrosequencing assay for drug-resistant tuberculosis diagnosis. BMC Infect Dis. 2016 08 31; 16:458.
-
Ereshefsky BJ, Al-Hasan MN, Gokun Y, Martin CA. Comparison of ?-lactam plus aminoglycoside versus ?-lactam plus fluoroquinolone empirical therapy in serious nosocomial infections due to Gram-negative bacilli. J Chemother. 2017 Feb; 29(1):30-37.
-
Mitsugi R, Sumida K, Fujie Y, Tukey RH, Itoh T, Fujiwara R. Acyl-glucuronide as a Possible Cause of Trovafloxacin-Induced Liver Toxicity: Induction of Chemokine (C-X-C Motif) Ligand 2 by Trovafloxacin Acyl-glucuronide. Biol Pharm Bull. 2016; 39(10):1604-1610.
-
Avalos E, Catanzaro D, Catanzaro A, Ganiats T, Brodine S, Alcaraz J, Rodwell T. Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review. PLoS One. 2015; 10(3):e0120470.
-
Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp L, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet. 2015 May 02; 385(9979):1738-1747.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|